Why the Pharmaceutical Industry Needs Implementation Science for Sustainable Innovation Anthony J. Messina Commentary Open access 02 May 2025
Artificial Intelligence: Applications in Pharmacovigilance Signal Management Jeffrey WarnerAnaclara Prada JardimClaudia Albera Review Article Open access 21 April 2025
Challenges to Establishing Pharmaceutical Medicine as a Profession: Needs for Professional Identity and a Career Pathway: Role of Education and Training Honorio SilvaVarvara BaroutsouIngrid Klingmann Current Opinion 19 April 2025
Shifting Paradigms in Medicines Development as a Profession: To Be or Not To Be Soneil GupthaDomenico Criscuolo Commentary 16 April 2025
Importance of Health Economics and Outcomes Research in the Product Lifecycle Amit Dang Review Article 14 April 2025
Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies Norihiro OkadaYosuke Takahashi Original Research Article Open access 11 April 2025
Correction: The Value and Importance of a Professional Ethical Code for Medicines Development: IFAPP International Ethics Framework Sandor Kerpel-FroniusAlexander L. BeckerMembers of the IFAPP Ethics Working Group Correction Open access 26 March 2025
Compliance with Cyproterone Contraindications and Meningioma Risk: Resource-Efficient Use of Aggregated Statistics from Swedish National Health Registers Karl Mikael KälknerAnders SundströmRickard Ljung Research Letter 15 March 2025 Pages: 143 - 145
Visionary Health Architects and Leaders: The Strategic Role of Medical Advisors in Modern Pharma Selene García-GarcíaJoan Rius-Tarruella Current Opinion 15 March 2025 Pages: 87 - 95
Embracing Medicines Development as a Profession Pravin Chopra Current Opinion Open access 13 March 2025
Innovation in the Design of Clinical Trials for Infectious Diseases: Focusing on Patients Over Pathogens John H. Powers IIIRobert J. O’Connell Current Opinion Open access 12 March 2025 Pages: 73 - 86
Suggested Improvements to the Current East African Community Medicines Regulatory Harmonization Joint Review Process and a Proposed New Review Model for this Initiative Nancy NgumChimwemwe ChamdimbaSam Salek Original Research Article Open access 04 March 2025 Pages: 125 - 141
Disproportionality Analysis and Causal Inference in Drug Safety Emil ScosyrevSigrid BehrChristiane Michel Current Opinion 04 March 2025 Pages: 97 - 107
The Economic Impact of Reliance on an African Medicines Regulatory Authority Lorraine DanksBoitumelo Semete-MakokotlelaSam Salek Original Research Article Open access 02 March 2025 Pages: 109 - 123
The Importance of Including Underserved Populations in Research Kayla R. MehlStephanie R. MorainEmily A. Largent Leading Article 01 April 2025 Pages: 59 - 71
Professional Competencies and Capabilities in the Development of Medicines Peter D. StonierStuart A. Jones Current Opinion Open access 16 February 2025
The Value and Importance of a Professional Ethical Code for Medicines Development: IFAPP International Ethics Framework Sandor Kerpel-FroniusAlexander L. BeckerMembers of the IFAPP Ethics Working Group Leading Article Open access 28 January 2025
Pricing and Impact: Understanding Sales Trends and Price-Volume Distributions of Antihypertensive Drugs in Europe, USA, and India Gautam SatheeshSwagata Kumar SahooAbdul Salam Research Letter 18 January 2025 Pages: 51 - 54
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research Joohyun YoonMegan R. MayerJoshua T. Kantrowitz Original Research Article 11 January 2025 Pages: 29 - 38
The Evolution of In-Field Medical Affairs: Introducing the Strategic Scientific Advisor Lucía Regadera AnechinaInmaculada IglesiasAna Pérez Domínguez Leading Article Open access 21 February 2025 Pages: 19 - 27
Contraception Requirements in Early Clinical Trials: Considerations Towards an Evidence-Based Approach Tatyana DubichAd F. Roffel Current Opinion 22 February 2025 Pages: 5 - 17
Author’s Reply to Pongpirul: “The Pharmaceutical Year that was, 2024” Anthony W. Fox Letter to the Editor 24 December 2024 Pages: 57 - 58
Comment on: “The Pharmaceutical Year that was, 2024” Krit Pongpirul Letter to the Editor 24 December 2024 Pages: 55 - 56
Understanding the National Healthcare Ecosystem to Position Medical Affairs as a Strategic Element: Lessons Learned from AstraZeneca Spain Inmaculada IglesiasJorge A. MarinichAna Pérez Domínguez Original Research Article Open access 23 December 2024 Pages: 39 - 50
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review Elif CarYannick VandenplasLiese Barbier Systematic Review Open access 29 November 2024 Pages: 429 - 455
European Pharmaceutical Industry Medical Information: A Role to Play in the Provision of Medicine-Related Information to Patients Ana BarriasEsther Di Lauroon behalf of MILE (Medical Information Leaders in Europe) Current Opinion Open access 13 November 2024 Pages: 399 - 405
Addressing Challenges in Antibiotic Access: Barriers, Implications and Strategies for Solution Ritika Kondel BhandariAvaneesh Kumar PandeyNusrat Shafiq Current Opinion 19 October 2024 Pages: 387 - 397
Transdermal Drug Delivery Systems: Different Generations and Dermatokinetic Assessment of Drug Concentration in Skin Rahul KushwahaNarahari N. Palei Review Article 14 October 2024 Pages: 407 - 427
Automated Mass Extraction of Over 680,000 PICOs from Clinical Study Abstracts Using Generative AI: A Proof-of-Concept Study Tim ReasonJulia LanghamAndy Gimblett Original Research Article Open access 26 September 2024 Pages: 365 - 372
Artificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities Emma FrölingNeda RajaeeanChristian Lenz Current Opinion Open access 11 September 2024 Pages: 331 - 342
Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists Yoshiko MaedaAkihito AbeMotonobu Sakaguchi Original Research Article Open access 21 August 2024 Pages: 373 - 380
P.O.L.A.R. Star: A New Framework Developed and Applied by One Mid-Sized Pharmaceutical Company to Drive Digital Transformation in R&D Riccardo MarianiMaria Carmela De VuonoDiego Ardigò Current Opinion Open access 09 August 2024 Pages: 343 - 353
Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs Florian ReisNeda RajaeeanClara Craesmeyer Current Opinion 01 August 2024 Pages: 355 - 363
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA Victor L. Van de WieleAaron S. KesselheimBenjamin N. Rome Original Research Article 14 July 2024 Pages: 303 - 310
Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods Eugenia BastosJeff K. AllenJeff Philip Original Research Article 13 July 2024 Pages: 321 - 329
How Can General Managers Best Leverage Medical Affairs Now and in the Future? Jon ZdonGreta-James ChatgilaouJosie Downey Current Opinion Open access 13 July 2024 Pages: 277 - 290
Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials Gareth BaynamSimeón BakerAnne Pariser Leading Article 09 July 2024 Pages: 261 - 276
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder Malia A. BelnapKaitlin R. McManusLara A. Ray Review Article Open access 05 July 2024 Pages: 291 - 302
Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences Cecilia PetrusHolly Lam Original Research Article Open access 28 June 2024 Pages: 311 - 320
Conducting Drug Treatment Trials in Children: Opportunities and Challenges Damir ErcegMarina JakirovićMirjana Turkalj Review Article 10 May 2024 Pages: 179 - 204
Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria Uchenna Geraldine ElemuwaFraden BitrusChristiana Mojisola Adeyeye Original Research Article 06 May 2024 Pages: 251 - 259
Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments Ryosuke KuribayashiAya HariuYasuhiro Kishioka Original Research Article 29 April 2024 Pages: 225 - 239
Redefining the Role of Medical Affairs Professionals as Innovators and Leaders in Industry-Led Medical Education Sajita SetiaElliot LooKaran Thakkar Current Opinion 15 April 2024 Pages: 167 - 177
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings Feng SunAlexander BedenkovCarmen Moreno Current Opinion Open access 04 April 2024 Pages: 157 - 166
A Sponsor’s Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan Kevin D. WolterAsayuki KamataniRod Junor Original Research Article Open access 31 March 2024 Pages: 217 - 224
Authorized or Off-Label Use? A Structured Analysis of Summaries of Product Characteristics with Regard to Authorization in Pediatrics Markus HerzigSimone EisenhoferMartina Patrizia Neininger Original Research Article Open access 31 March 2024 Pages: 205 - 216
Survey on the Situation of Medical Departments in the Pharmaceutical Industry in Spain Isabel Sanchez-MagroSusana Gomez-LusPablo Viguera Original Research Article Open access 21 March 2024 Pages: 241 - 250
Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges Shubhadeep D. SinhaSreenivasa Chary SriramadasuSudeshna Roy Review Article 07 March 2024 Pages: 109 - 120
